Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy

Stopped early · Phase 2

Conditions studied: Hypertriglyceridemia

In brief

The purpose of this study is to determine if implitapide is effective in lowering triglyceride (TG) levels in patients with Fredrickson Type I or V hypertriglyceridemia where the maximum tolerable medication and diet were not sufficient.

Key facts

Study ID

NCT00080132

Run by

Medical Research Laboratories International

People needed

50

Starts

2004-10-01

Expected to finish

2005-04-01

Last updated by the study team

2005-06-24

Who can join

Age: 8 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• In order to participate in this study, patients must meet all of the following inclusion criteria:
• be between 8 and 70 years old with diagnosis of Fredrickson Type I or V HTG
• be stable on current maximum tolerated triglyceride lowering therapy
• have a fasting TG level of at least 880 mg/dL (10 mmol/L)
• be male or nonpregnant, nonbreastfeeding female. The women in the study must be surgically sterile, postmenopausal or must practice an effective method of birth control
• must be able to give informed consent or if under the age of 18, parents or legal guardians must give their informed consent
• meet body weight requirements

You may not qualify if…

• Recent heart attack, coronary artery intervention, coronary bypass surgery, or stroke.
• Patients with class 3 or 4 heart failure
• Uncontrolled hypothyroidism or other uncontrolled endocrine disease
• Known, clinically significant eye abnormalities, such as cataracts
• History of hepatic disease or AST or ALT levels greater than 1.5 x ULN at Visit 1
• Alkaline phosphatase greater than 2 times ULN
• Serum creatinine greater than 2.0 mg/dL
• Liver cirrhosis and severe liver steatosis
• Clinically significant infection, malignancy, or psychosis
• Use of oral anticoagulants or digoxin unless the dose is stable and is regularly monitored
• Participation in any other investigational study within the last 30 days
• Breastfeeding or pregnant
• Current drug or alcohol abuse
• Serious or unstable medical conditions that would compromise the patient's safety or successful participation in the study
• Unwillingness to comply with study procedures or unwillingness to cooperate fully

Where it is running

• Metabolic and Atherosclerosis Research Center — Cincinnati, Ohio, United States
• The Methodist Hospital — Houston, Texas, United States
• Academic Medical Center Amsterdam — Amsterdam, Netherlands
• Andromed Noord — Groningen, Netherlands
• Andromed Leiden — Leiden, Netherlands
• Andromed Rotterdam — Rotterdam, Netherlands
• Andromed Oost — Velp, Netherlands
• Andromed Zoetermeer — Zoetermeer, Netherlands
• Lipidklinikken - Rikshospitalet — Oslo, Norway

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.